Branched Polymer-Drug Conjugates for Multivalent Blockade of Angiotensin II Receptors

Molecular Pharmaceutics

Volumn 12, Issue 9, 2015, Pages 3292-3302

  Hennig, Robert ^a   Veser, Anika ^a   Kirchhof, Susanne ^a   Goepferich, Achim ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

angiotensin receptor blocker; EXP3174; half life extension; multivalency; PAMAM dendrimers; PEGylation

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN RECEPTOR; DENDRIMER; MACROGOL; POLYAMIDOAMINE; POLYMER; ANTIHYPERTENSIVE AGENT; DRUG CARRIER; IMIDAZOLE DERIVATIVE; LIGAND; MACROGOL DERIVATIVE; PAMAM STARBURST; POLYAMINE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; EYE DISEASE; IC50; IN VITRO STUDY; L929 CELL LINE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA NEOVASCULARIZATION; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HALF LIFE TIME; MESODERM; METABOLISM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELLS, CULTURED; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HALF-LIFE; IMIDAZOLES; LIGANDS; MESODERM; POLYAMINES; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 84941077595     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00301     Document Type: Article

References (63)

1. Moravski, C. J.; Kelly, D. J.; Cooper, M. E.; Gilbert, R. E.; Bertram, J. F.; Shahinfar, S.; Skinner, S. L.; Wilkinson-Berka, J. L. Retinal neovascularization is prevented by blockade of the renin-angiotensin system Hypertension 2000, 36, 1099-1104 10.1161/01.HYP.36.6.1099
2. Nagai, N.; Izumi-Nagai, K.; Oike, Y.; Koto, T.; Satofuka, S.; Ozawa, Y.; Yamashiro, K.; Inoue, M.; Tsubota, K.; Umezawa, K.; Ishida, S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway Invest. Ophthalmol. Visual Sci. 2007, 48, 4342-4350 10.1167/iovs.06-1473
3. Nakamura, S.; Tsuruma, K.; Shimazawa, M.; Hara, H. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression Eur. J. Pharmacol. 2012, 685, 8-14 10.1016/j.ejphar.2012.04.017
4. Chaturvedi, N.; Porta, M.; Klein, R.; Orchard, T.; Fuller, J.; Parving, H. H.; Bilous, R.; Sjølie, A. K. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 2008, 372, 1394-1402 10.1016/S0140-6736(08)61412-9
5. Israili, Z. H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J. Hum. Hypertens. 2000, 14 (Suppl. 1) S73-86 10.1038/sj.jhh.1000991
6. Dinh, D. T.; Frauman, A. G.; Johnston, C. I.; Fabiani, M. E. Angiotensin receptors: distribution, signalling and function Clin. Sci. 2001, 100, 481-492 10.1042/cs1000481
7. Byon, I. S.; Jeon, H. S.; Kim, H. W.; Lee, S. J.; Lee, J. E.; Oum, B. S. The effect of a systemic angiotensin receptor blocker on vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy Curr. Eye Res. 2013, 38, 774-780 10.3109/02713683.2013.772206
8. Krohne, T. U.; Eter, N.; Holz, F. G.; Meyer, C. H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am. J. Ophthalmol. 2008, 146, 508-512 10.1016/j.ajo.2008.05.036
9. Lee, J. E.; Lim, D. W.; Park, H. J.; Shin, J. H.; Lee, S. M.; Oum, B. S. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model Invest. Ophthalmol. Visual Sci. 2011, 52, 2924-2929 10.1167/iovs.10-5850
10. Moshfeghi, A. A.; Puliafito, C. A. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration Expert Opin. Invest. Drugs 2005, 14, 671-682 10.1517/13543784.14.5.671
11. Fishburn, C. S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 2008, 97, 4167-4183 10.1002/jps.21278
12. Alcantar, N. A.; Aydil, E. S.; Israelachvili, J. N. Polyethylene glycol-coated biocompatible surfaces J. Biomed. Mater. Res. 2000, 51, 343-351 10.1002/1097-4636(20000905)51:3<343::AID-JBM7>3.0.CO;2-D
13. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 2011, 22, 868-876 10.1016/j.copbio.2011.06.012
14. Iezzi, R.; Guru, B. R.; Glybina, I. V.; Mishra, M. K.; Kennedy, A.; Kannan, R. M. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration Biomaterials 2012, 33, 979-988 10.1016/j.biomaterials.2011.10.010
15. Kambhampati, S. P.; Clunies-Ross; Alexander, J. M.; Bhutto, I.; Mishra, M. K.; Edwards, M.; McLeod, D. S.; Kannan, R. M.; Lutty, G. Systemic and Intravitreal Delivery of Dendrimers to Activated Microglia/Macrophage in Ischemia/Reperfusion Mouse Retina Invest. Ophthalmol. Visual Sci. 2015, 56, 4413-4424 10.1167/iovs.14-16250
16. Hennig, R.; Pollinger, K.; Veser, A.; Breunig, M.; Goepferich, A. Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation J. Controlled Release 2014, 194, 20-27 10.1016/j.jconrel.2014.07.062
17. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity Adv. Drug Delivery Rev. 2005, 57, 2215-2237 10.1016/j.addr.2005.09.019
18. Jiang, Y.-Y.; Tang, G.-T.; Zhang, L.-H.; Kong, S.-Y.; Zhu, S.-J.; Pei, Y.-Y. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex J. Drug Target. 2010, 18, 389-403 10.3109/10611860903494203
19. Kolhe, P.; Misra, E.; Kannan, R. M.; Kannan, S.; Lieh-Lai, M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers Int. J. Pharm. 2003, 259, 143-160 10.1016/S0378-5173(03)00225-4
20. Dougherty, C. A.; Furgal, J. C.; van Dongen, M. A.; Goodson, T.; Banaszak Holl, M. M.; Manono, J.; DiMaggio, S. Isolation and characterization of precise dye/dendrimer ratios Chem.-Eur. J. 2014, 20, 4638-4645 10.1002/chem.201304854
21. Wängler, C.; Moldenhauer, G.; Saffrich, R.; Knapp, E.-M.; Beijer, B.; Schnölzer, M.; Wängler, B.; Eisenhut, M.; Haberkorn, U.; Mier, W. PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules Chem.-Eur. J. 2008, 14, 8116-8130 10.1002/chem.200800328
22. Grynkiewicz, G.; Poenie, M.; Tsien, R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties J. Biol. Chem. 1985, 260, 3440-3450
23. Brandl, F.; Hammer, N.; Blunk, T.; Tessmar, J.; Goepferich, A. Biodegradable hydrogels for time-controlled release of tethered peptides or proteins Biomacromolecules 2010, 11, 496-504 10.1021/bm901235g
24. Ritter, M. A.; Furtek, C. I.; Lo, M. W. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection J. Pharm. Biomed. Anal. 1997, 15, 1021-1029 10.1016/S0731-7085(96)01948-6
25. van Dongen, M. A.; Desai, A.; Orr, B. G.; Baker, J. R.; Banaszak Holl, M. M. Quantitative analysis of generation and branch defects in G5 poly(amidoamine) dendrimer Polymer 2013, 54, 4126-4133 10.1016/j.polymer.2013.05.062
26. van Dongen, M. A.; Orr, B. G.; Banaszak Holl, M. M. Diffusion NMR study of generation-five PAMAM dendrimer materials J. Phys. Chem. B 2014, 118, 7195-7202 10.1021/jp504059p
27. Gasparo, M. de; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol. Rev. 2000, 52, 415-472
28. Huang, C.; Ramadan, Q.; Wacker, J. B.; Tekin, H. C.; Ruffert, C.; Vergères, G.; Silacci, P.; Gijs, M. A. M. Microfluidic chip for monitoring Ca 2+ transport through a confluent layer of intestinal cells RSC Adv. 2014, 4, 52887-52891 10.1039/C4RA09370D
29. Mu, Q.; Hu, T.; Yu, J. Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation PLoS One 2013, 8, e68559 10.1371/journal.pone.0068559
30. Treetharnmathurot, B.; Ovartlarnporn, C.; Wungsintaweekul, J.; Duncan, R.; Wiwattanapatapee, R. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin Int. J. Pharm. 2008, 357, 252-259 10.1016/j.ijpharm.2008.01.016
31. Fee, C. J.; Van Alstine, J. M. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjugate Chem. 2004, 15, 1304-1313 10.1021/bc049843w
32. García-Arellano, H.; Valderrama, B.; Saab-Rincón, G.; Vazquez-Duhalt, R. High Temperature Biocatalysis by Chemically Modified Cytochrome c Bioconjugate Chem. 2002, 13, 1336-1344 10.1021/bc025561p
33. Christ, D. D. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174 J. Clin. Pharmacol. 1995, 35, 515-520 10.1002/j.1552-4604.1995.tb04097.x
34. Yan, Y.-D.; Kim, H.-K.; Seo, K.-H.; Lee, W. S.; Lee, G.-S.; Woo, J.-S.; Yong, C.-S.; Choi, H.-G. The Physicochemical Properties, in Vitro Metabolism and Pharmacokinetics of a Novel Ester Prodrug of EXP3174 Mol. Pharmaceutics 2010, 7, 2132-2140 10.1021/mp100166c
35. Cakara, D.; Kleimann, J.; Borkovec, M. Microscopic Protonation Equilibria of Poly(amidoamine) Dendrimers from Macroscopic Titrations Macromolecules 2003, 36, 4201-4207 10.1021/ma0300241
36. Niu, Y.; Sun, L.; Crooks, R. M. Determination of the Intrinsic Proton Binding Constants for Poly(amidoamine) Dendrimers via Potentiometric pH Titration Macromolecules 2003, 36, 5725-5731 10.1021/ma034276d
37. Ramzi, A.; Scherrenberg, R.; Brackman, J.; Joosten, J.; Mortensen, K. Intermolecular Interactions between Dendrimer Molecules in Solution Studied by Small-Angle Neutron Scattering Macromolecules 1998, 31, 1621-1626 10.1021/ma970974k
38. Svenson, S.; Tomalia, D. A. Dendrimers in biomedical applications - reflections on the field Adv. Drug Delivery Rev. 2005, 57, 2106-2129 10.1016/j.addr.2005.09.018
39. Maiti, P. K.; Çaʇln, T.; Lin, S.-T.; Goddard, W. A. Effect of Solvent and pH on the Structure of PAMAM Dendrimers Macromolecules 2005, 38, 979-991 10.1021/ma049168l
40. Pavan, G. M.; Albertazzi, L.; Danani, A. Ability to adapt: different generations of PAMAM dendrimers show different behaviors in binding siRNA J. Phys. Chem. B 2010, 114, 2667-2675 10.1021/jp100271w
41. Mangold, S. L.; Cloninger, M. J. Binding of monomeric and dimeric Concanavalin A to mannose-functionalized dendrimers Org. Biomol. Chem. 2006, 4, 2458-2465 10.1039/b600066e
42. Hong, S.; Leroueil, P. R.; Majoros, I. J.; Orr, B. G.; Baker, J. R.; Banaszak Holl, M. M. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform Chem. Biol. 2007, 14, 107-115 10.1016/j.chembiol.2006.11.015
43. Tosh, D. K.; Yoo, L. S.; Chinn, M.; Hong, K.; Kilbey, S. M.; Barrett, M. O.; Fricks, I. P.; Harden, T. K.; Gao, Z.-G.; Jacobson, K. A. Polyamidoamine (PAMAM) dendrimer conjugates of clickable agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide Bioconjugate Chem. 2010, 21, 372-384 10.1021/bc900473v
44. van Dongen, M. A.; Silpe, J. E.; Dougherty, C. A.; Kanduluru, A. K.; Choi, S. K.; Orr, B. G.; Low, P. S.; Banaszak Holl, M. M. Avidity mechanism of dendrimer-folic acid conjugates Mol. Pharmaceutics 2014, 11, 1696-1706 10.1021/mp5000967
45. Bao, X.; Wang, W.; Wang, C.; Wang, Y.; Zhou, J.; Ding, Y.; Wang, X.; Jin, Y. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy Biomaterials 2014, 35, 8450-8466 10.1016/j.biomaterials.2014.06.025
46. Ruckman, J.; Green, L. S.; Beeson, J.; Waugh, S.; Gillette, W. L.; Henninger, D. D.; Claesson-Welsh, L.; Janjić, N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J. Biol. Chem. 1998, 273, 20556-20567 10.1074/jbc.273.32.20556
47. Drolet, D. W.; Nelson, J.; Tucker, C. E.; Zack, P. M.; Nixon, K.; Bolin, R.; Judkins, M. B.; Farmer, J. A.; Wolf, J. L.; Gill, S. C.; Bendele, R. A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys Pharm. Res. 2000, 17, 1503-1510 10.1023/A:1007657109012
48. Ng, E. W. M.; Shima, D. T.; Calias, P.; Cunningham, E. T.; Guyer, D. R.; Adamis, A. P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discovery 2006, 5, 123-132 10.1038/nrd1955
49. Jie, P.; Venkatraman, S. S.; Min, F.; Freddy, B. Y. C.; Huat, G. L. Micelle-like nanoparticles of star-branched PEO-PLA copolymers as chemotherapeutic carrier J. Controlled Release 2005, 110, 20-33 10.1016/j.jconrel.2005.09.011
50. Ding, H.; Yong, K.-T.; Roy, I.; Hu, R.; Wu, F.; Zhao, L.; Law, W.-C.; Zhao, W.; Ji, W.; Liu, L.; Bergey, E. J.; Prasad, P. N. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers Nanotechnology 2011, 22, 165101 10.1088/0957-4484/22/16/165101
51. Orienti, I.; Zuccari, G.; Falconi, M.; Teti, G.; Illingworth, N. A.; Veal, G. J. Novel micelles based on amphiphilic branched PEG as carriers for fenretinide Nanomedicine 2012, 8, 880-890 10.1016/j.nano.2011.10.008
52. Kalyanasundaram, K.; Thomas, J. K. Environmental effects on vibronic band intensities in pyrene monomer fluorescence and their application in studies of micellar systems J. Am. Chem. Soc. 1977, 99, 2039-2044 10.1021/ja00449a004
53. Nakajima, A. Fluorescence spectra of anthracene and pyrene in water and in aqueous surfactant solution J. Lumin. 1977, 15, 277-282 10.1016/0022-2313(77)90027-8
54. Roberts, J. C.; Bhalgat, M. K.; Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) StarburstTM dendrimers J. Biomed. Mater. Res. 1996, 30, 53-65 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
55. Jain, K.; Kesharwani, P.; Gupta, U.; Jain, N. K. Dendrimer toxicity: Let's meet the challenge Int. J. Pharm. 2010, 394, 122-142 10.1016/j.ijpharm.2010.04.027
56. Wang, W.; Xiong, W.; Wan, J.; Sun, X.; Xu, H.; Yang, X. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress Nanotechnology 2009, 20, 105103 10.1088/0957-4484/20/10/105103
57. Naha, P. C.; Davoren, M.; Lyng, F. M.; Byrne, H. J. Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells Toxicol. Appl. Pharmacol. 2010, 246, 91-99 10.1016/j.taap.2010.04.014
58. Labieniec, M.; Gabryelak, T. Preliminary biological evaluation of poli(amidoamine) (PAMAM) dendrimer G3.5 on selected parameters of rat liver mitochondria Mitochondrion 2008, 8, 305-312 10.1016/j.mito.2008.07.001
59. Lee, J.-H.; Cha, K. E.; Kim, M. S.; Hong, H. W.; Chung, D. J.; Ryu, G.; Myung, H. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction Toxicol. Lett. 2009, 190, 202-207 10.1016/j.toxlet.2009.07.018
60. Waite, C. L.; Sparks, S. M.; Uhrich, K. E.; Roth, C. M. Acetylation of PAMAM dendrimers for cellular delivery of siRNA BMC Biotechnol. 2009, 9, 38 10.1186/1472-6750-9-38
61. Fant, K.; Esbjörner, E. K.; Jenkins, A.; Grossel, M. C.; Lincoln, P.; Nordén, B. Effects of PEGylation and acetylation of PAMAM dendrimers on DNA binding, cytotoxicity and in vitro transfection efficiency Mol. Pharmaceutics 2010, 7, 1734-1746 10.1021/mp1001312
62. Labieniec, M.; Watala, C. PAMAM dendrimers -diverse biomedical applications. Facts and unresolved questions Cent. Eur. J. Biol. 2009, 4, 434-451 10.2478/s11535-009-0056-7
63. Zhou, D.; Kim, S. H.; Carroll, V. M.; Dence, C. S.; Katzenellenbogen, J. A. Utilizing electrostatic interactions to facilitate F-18 radiolabeling of poly(amido)amine (PAMAM) dendrimers Org. Biomol. Chem. 2014, 12, 8696-8701 10.1039/C4OB01616E